Extramedullary relapse after all-trans retinoic acid treatment in acute promyelocytic leukemia - The occurrence of retinoic acid syndrome is a risk factor

Leukemia

Volumn 13, Issue 9, 1999, Pages 1406-1408

  Ko, B S ^a   Tang, J L ^a   Chen, Y C ^a   Yao, M ^a   Wang, C H ^a   Shen, M C ^a   Tien, H F ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Extramedullary disease; Retinoic acid syndrome

Indexed keywords

ANTINEOPLASTIC AGENT; RETINOIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE PREDISPOSITION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; RETINOIC ACID SYNDROME; RISK FACTOR;

EID: 0032870982     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401495     Document Type: Article

References (16)

1. Stone RM, Mayer RJ. The unique aspects of acute promyelocytic leukemia. J Clin Oncol 1990; 8: 1913-1921.
2. Huang M, Ye Y, Chen S, Chai J, Lu J, Zhoa L et al. Use of all-trans retinoid acid in the treatment of acute myelocytic leukemia. Blood 1988; 72: 67-72.
3. Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Duarte M, Morel P et al. Effect of all-trans retinoid acid in newly diagnosed acute promyelocytic leukemia: results of a multicenter randomized trial. Blood 1993; 82: 3241-3249.
4. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr. The 'retinoid acid' syndrome in acute promyelocytic leukemia. Ann Intern Med 1992; 117: 292-296.
5. Weiss MA, Warrell RP Jr. Two cases of extramedullary acute promyelocytic leukemia. Cancer 1994; 74: 1882-1886.
6. Wiernik PH, Bellis RD, Muxi P, Dutcher JP. Extramedullary acute promyelocytic leukemia. Cancer 1996; 78: 2510-2514.
7. Evans G, Grimwade D, Prentice HG, Simpson N. Central nerve system relapse in acute promyelocytic leukaemia in patients treated with all-trans retinoic acid. Br J Haematol 1997; 98: 437-439.
8. Chou WC, Tang JL, Yao M, Liang YJ, Lee FY, Lin MT, Wang CH, Shen MC, Chen YC, Tien HF. Clinical and biological characteristics of acute promyelocytic leukemia in Taiwan: a high relapse rate in patients with high initial and peak white blood cell counts during all-trans retinoic acid treatment. Leukemia 1997; 11: 921-928.
9. Bernekli M, Savas MC, Haznedaroglu IC, Dundar SV. Granulocytic sarcoma in acute promyelocytic leukaemia. Leuk Lymphoma 1996; 26: 417-418.
10. Ueda K, Kume A, Furukawa Y, Higashi N. Cutaneous infiltration in acute promyelocytic leukemia. J Am Acad Dermatol 1997; 36: 104-106.
11. Warrell RP Jr, Frankel S, Miller W, Scheinberg D, Itri L, Hittelman W et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoid acid). New Engl J Med 1991; 324: 1385-1393.
12. Saiki I, Fujii H, Abe A. Roles of aminopeptidase N (CD13) in tumor cell invasion and extracellular matrix degeneration. Int J Cancer 1993; 54: 137-140.
13. Vahdat L, Masiak P, Miller WH Jr, Eardley A, Heller G, Scheinberg DA, Warrell RP Jr. Early mortality and the retinoic acid syndrome in acute promyelocytic leukaemia: impact of leukocytosis, low-dose chemotherapy, PML/RARa isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 1996; 84: 3843-3849.
14. Warrell RP Jr, Maslak P, Eardley A, Heller G, Miller WH Jr, Frankel SR. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. Leukemia 1994; 8: 929-933.
15. Fenaux P, Chastang C, Chomienne C, Castaigne S, Sanz M, Link H, Lowenberg B, Fey M, Archimbaud E, Degos L et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL) by all-trans retinoic acid (ATRA) combined with chemotherapy: the European experience. European APL group. Leuk Lymphoma 1995; 16: 431-437.
16. Fenaux P, Chastang C, Sanz M, Thomas X, Dombret H, Link H, Guerci A, Fegueux N, San Miguel J, Degos L et al. ATRA followed by chemotherapy (CT) vs. ATRA plus CT and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia (APL): first interim results of APL 93 trial. Blood 1997; 90: 122a.